TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial
Open Access
- 17 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 122 (7), 971-977
- https://doi.org/10.1038/s41416-020-0752-7
Abstract
Background TG01 is the first cancer immunotherapy targeting KRAS oncogenic mutations. This study assessed the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma. Methods Patients with stage I or II pancreatic adenocarcinoma who had undergone surgical resection (R0 or R1) received adjuvant gemcitabine with TG01/GM-CSF using two schedules of vaccination. Immune response was defined as a positive delayed-type hypersensitivity (DTH) response and/or positive T-cell proliferation assay. Results Thirty-two patients were enrolled between February 2013 and May 2016. Nineteen were treated with the high antigen burden, with four serious adverse reactions considered possibly related to TG01 treatment, including three allergic reactions. On this basis, a further 13 patients received a modified vaccination schedule with reduced antigen burden, with no serious adverse events related to TG01. Ninety-five percent patients in the main cohort and 92% in the modified cohort had a positive immune response. Median overall survival (OS) was 33.1 months, and median disease-free survival (DFS) was 13.9 months for the main cohort. For the modified cohort, the median OS was 34.3 months and median DFS was 19.5 months. Conclusions TG01/GM-CSF with gemcitabine was well tolerated, with high levels of immune activation. OS and DFS compare favourably with published data for adjuvant gemcitabine. Clinical trial registration This clinical trial was registered at ClinicalTrials.gov (NCT02261714).Keywords
Funding Information
- Targovax ASA, The Research Council of Norway, Innovation Norway
This publication has 20 references indexed in Scilit:
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJama-Journal Of The American Medical Association, 2013
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II StudyJournal of Clinical Oncology, 2010
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJama-Journal Of The American Medical Association, 2010
- Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐rasInternational Journal of Cancer, 2010
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJama-Journal Of The American Medical Association, 2007
- Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical marginsGut, 2006
- Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II studyBritish Journal of Cancer, 2006
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerThe New England Journal of Medicine, 2004
- Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinomaInternational Journal of Cancer, 2001
- Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.Environmental Health Perspectives, 1991